Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Trimmed by JPMorgan Chase & Co.

JPMorgan Chase & Co. cut its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 13.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,919,929 shares of the biopharmaceutical company’s stock after selling 1,984,751 shares during the quarter. JPMorgan Chase & Co. owned about 4.32% of Amicus Therapeutics worth $137,985,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Xponance Inc. boosted its stake in Amicus Therapeutics by 5.3% in the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 936 shares during the period. Hazlett Burt & Watson Inc. boosted its position in shares of Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares during the period. Arizona State Retirement System grew its holdings in shares of Amicus Therapeutics by 2.6% during the second quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after buying an additional 1,577 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Amicus Therapeutics by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 1,884 shares during the period. Finally, OLD Second National Bank of Aurora purchased a new stake in Amicus Therapeutics in the 3rd quarter worth about $26,000.

Insider Activity

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $11,083,175. The trade was a 0.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have sold 22,901 shares of company stock valued at $259,863. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $9.42 on Thursday. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.53. The stock’s 50-day moving average is $10.21 and its two-hundred day moving average is $10.57. The firm has a market cap of $2.81 billion, a P/E ratio of -27.71 and a beta of 0.60. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on FOLD. Bank of America upped their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Cantor Fitzgerald increased their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Morgan Stanley restated an “equal weight” rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Guggenheim boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.88.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.